Table 2 Pharmacokinetic parameters of BBI-2779 indicate that it is well tolerated in mice

From: Enhancing transcription–replication conflict targets ecDNA-positive cancers

Pharmacokinetic parameter

BBI-2779

In vivo cl (ml min−1 kg−1)

229

t1/2 (h)

1.11

tmax (h)

0.5

Cmax (ng ml–1)

713

AUCinf (h ng ml–1)

1,568

%F

72

  1. Oral bioavailability was determined in fasted male CD-1 mice dosed at 30 mg kg−1 (n = 3). AUCinf, area under concentration-time curve; cl, plasma clearance; Cmax, maximum observed concentration; %F, % oral bioavailability; t1/2, terminal half life; tmax, time maximum concentration.
Back to article page